Search

ATL1102

ATL1102 is a second-generation antisense inhibitor of CD49d, an immunesystem protein known as VLA-4, an immune cell molecule. It works by entering cells and targeting genes.

CERE-110

CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. This drug is developed by Ceregene and currently under phase I of clinic...

Acetylcysteine zidrimer

Sapacitabine

Varlitinib

Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlit...

CT-011

CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating a...

ASI402

ASI402 is a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1. It is being investigated in cancers.

ENMD-1198

Cefpiramide

Cefpiramide is a third-generation cephalosporin antibiotic.

Tagetitoxin

Tagetitoxin is a bacterial phytotoxin. It preferentially inhibits eukaryotic RNA polymerase.